https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-15 / Immunopharmacol Immunotoxicol 2012 Jun;34(3):465-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-15 / Immunopharmacol Immunotoxicol 2012 Jun;34(3):465-92011-10-15 00:00:002019-02-15 08:46:01Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-306
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-3062011-10-03 00:00:002019-02-15 08:52:46Current vaccination strategies for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-72011-10-01 00:00:002019-02-15 08:53:13Proving the principle: dendritic cell-based vaccines in urogenital cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-28 / Clin. Dev. Immunol. 2011;2011:249281
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-28 / Clin. Dev. Immunol. 2011;2011:2492812011-09-28 00:00:002020-01-08 10:10:19Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-842011-09-17 00:00:002019-02-15 08:52:16A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-14 / Clin. Dev. Immunol. 2011;2011:267539
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-14 / Clin. Dev. Immunol. 2011;2011:2675392011-09-14 00:00:002019-02-15 08:52:31Current immunotherapeutic approaches in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-722011-08-31 00:00:002019-02-15 08:46:37Immunotherapy in human glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-16 / J. Mol. Med. 2011 Dec;89(12):1231-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-16 / J. Mol. Med. 2011 Dec;89(12):1231-402011-08-16 00:00:002019-02-15 08:50:07HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-852011-08-08 00:00:002019-02-15 08:52:48Immunotherapy for prostate cancer: biology and therapeutic approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-04 / Ger Med Sci 2011;9:Doc18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-04 / Ger Med Sci 2011;9:Doc182011-08-04 00:00:002019-02-15 08:45:26Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells
